CR20200180A - Compuesto de pirimidina como inhibidor de las janocinasas - Google Patents

Compuesto de pirimidina como inhibidor de las janocinasas

Info

Publication number
CR20200180A
CR20200180A CR20200180A CR20200180A CR20200180A CR 20200180 A CR20200180 A CR 20200180A CR 20200180 A CR20200180 A CR 20200180A CR 20200180 A CR20200180 A CR 20200180A CR 20200180 A CR20200180 A CR 20200180A
Authority
CR
Costa Rica
Prior art keywords
compound
kinase inhibitor
pyrimidine compound
jak kinase
formula
Prior art date
Application number
CR20200180A
Other languages
English (en)
Inventor
Ryan Hudson
Jennifer Kozak
Marta Dabros
Jerry Nzerem
Gary E L Brandt
Robert Murray Mckinnell
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CR20200180A publication Critical patent/CR20200180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)

Abstract

<p>La invención proporciona un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable de este, que es un inhibidor de las janocinasas (JAK). La invención también proporciona composiciones farmacéuticas que comprenden dicho compuesto, una forma cristalina, métodos de uso de dicho compuesto para tratar enfermedades inflamatorias de la piel y otras enfermedades, y procesos y productos intermedios útiles para preparar dicho compuesto.</p>
CR20200180A 2017-10-27 2018-10-26 Compuesto de pirimidina como inhibidor de las janocinasas CR20200180A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
PCT/US2018/057682 WO2019084383A1 (en) 2017-10-27 2018-10-26 PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
CR20200180A true CR20200180A (es) 2020-08-12

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200180A CR20200180A (es) 2017-10-27 2018-10-26 Compuesto de pirimidina como inhibidor de las janocinasas

Country Status (37)

Country Link
US (7) US10308646B2 (es)
EP (1) EP3672965B1 (es)
JP (1) JP7218364B2 (es)
KR (1) KR102613503B1 (es)
CN (1) CN111247142B (es)
AR (1) AR113803A1 (es)
AU (1) AU2018354370B2 (es)
BR (1) BR112020008015A2 (es)
CA (1) CA3074034A1 (es)
CL (1) CL2020001090A1 (es)
CR (1) CR20200180A (es)
CU (1) CU24671B1 (es)
DK (1) DK3672965T3 (es)
DO (1) DOP2020000083A (es)
EA (1) EA202091016A1 (es)
EC (1) ECSP20023795A (es)
ES (1) ES2932526T3 (es)
GE (1) GEP20227344B (es)
HR (1) HRP20221221T1 (es)
HU (1) HUE060401T2 (es)
IL (1) IL274037B2 (es)
LT (1) LT3672965T (es)
MA (1) MA49956B1 (es)
MD (1) MD3672965T2 (es)
MX (1) MX2020004255A (es)
NI (1) NI202000032A (es)
PE (1) PE20201495A1 (es)
PH (1) PH12020500528A1 (es)
PL (1) PL3672965T3 (es)
PT (1) PT3672965T (es)
RS (1) RS63608B1 (es)
SG (1) SG11202001706RA (es)
SI (1) SI3672965T1 (es)
TW (1) TWI789446B (es)
UA (1) UA125130C2 (es)
WO (1) WO2019084383A1 (es)
ZA (1) ZA202001641B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200180A (es) 2017-10-27 2020-08-12 Theravance Biopharma R&D Ip Llc Compuesto de pirimidina como inhibidor de las janocinasas
WO2020108613A1 (zh) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
CA3135388A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Pyrimidine jak inhibitors for the treatment of skin diseases
HRP20240346T1 (hr) 2019-04-24 2024-05-24 Theravance Biopharma R&D Ip, Llc Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze
JP7572538B2 (ja) 2020-07-28 2024-10-23 アーキュティス・バイオセラピューティクス・インコーポレーテッド Ｊａｋ阻害剤およびラウレス－４を含有する局所配合物
AU2021333760A1 (en) * 2020-08-26 2023-04-06 Nalo Therapeutics Modulators of Myc family proto-oncogene protein
EP4225438A1 (en) * 2020-10-08 2023-08-16 Icahn School of Medicine at Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4105947B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なトリアゾール化合物
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2588220A1 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
JP2009515992A (ja) 2005-11-16 2009-04-16 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なアミノピリミジン
EP2044063A1 (en) 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
CN104011050A (zh) 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (es) * 2014-08-21 2018-03-31
CN106687467A (zh) 2014-09-30 2017-05-17 韩美精密化学株式会社 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法
ES2753159T3 (es) * 2015-05-28 2020-04-07 Theravance Biopharma R&D Ip Llc Compuestos de naftiridina como inhibidores de quinasa JAK
JP2018527362A (ja) * 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換されたヘテロアリール化合物および使用方法
AU2017258186B2 (en) * 2016-04-28 2020-09-17 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as JAK kinase inhibitors
CR20200180A (es) * 2017-10-27 2020-08-12 Theravance Biopharma R&D Ip Llc Compuesto de pirimidina como inhibidor de las janocinasas
CA3135388A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Pyrimidine jak inhibitors for the treatment of skin diseases
HRP20240346T1 (hr) 2019-04-24 2024-05-24 Theravance Biopharma R&D Ip, Llc Esterski i karbonatni spojevi pirimidina kao inhibitori jak-kinaze

Also Published As

Publication number Publication date
US20220396573A1 (en) 2022-12-15
US20200369660A1 (en) 2020-11-26
ES2932526T3 (es) 2023-01-20
US20240158389A1 (en) 2024-05-16
US20210214349A1 (en) 2021-07-15
IL274037A (en) 2020-06-30
AR113803A1 (es) 2020-06-10
PE20201495A1 (es) 2020-12-29
US10308646B2 (en) 2019-06-04
US20190127364A1 (en) 2019-05-02
HUE060401T2 (hu) 2023-02-28
IL274037B1 (en) 2023-07-01
AU2018354370A1 (en) 2020-04-09
AU2018354370B2 (en) 2023-04-27
US11420965B2 (en) 2022-08-23
RS63608B1 (sr) 2022-10-31
NI202000032A (es) 2020-10-09
JP2021501151A (ja) 2021-01-14
MA49956A (fr) 2020-07-01
ZA202001641B (en) 2021-04-28
DK3672965T3 (da) 2022-10-03
US10562894B2 (en) 2020-02-18
PH12020500528A1 (en) 2021-06-07
HRP20221221T1 (hr) 2022-12-09
MX2020004255A (es) 2020-07-29
LT3672965T (lt) 2022-10-10
CA3074034A1 (en) 2019-05-02
US20190241555A1 (en) 2019-08-08
BR112020008015A2 (pt) 2020-10-27
US11814377B2 (en) 2023-11-14
US10988470B2 (en) 2021-04-27
EA202091016A1 (ru) 2020-07-17
CN111247142B (zh) 2022-12-02
IL274037B2 (en) 2023-11-01
SG11202001706RA (en) 2020-03-30
ECSP20023795A (es) 2020-06-30
CN111247142A (zh) 2020-06-05
KR102613503B1 (ko) 2023-12-13
SI3672965T1 (sl) 2022-11-30
TWI789446B (zh) 2023-01-11
EP3672965A1 (en) 2020-07-01
UA125130C2 (uk) 2022-01-12
PT3672965T (pt) 2022-09-29
KR20200078517A (ko) 2020-07-01
GEP20227344B (en) 2022-01-25
DOP2020000083A (es) 2020-08-15
PL3672965T3 (pl) 2023-01-16
MD3672965T2 (ro) 2022-12-31
WO2019084383A1 (en) 2019-05-02
US10774080B2 (en) 2020-09-15
CL2020001090A1 (es) 2020-08-21
EP3672965B1 (en) 2022-09-07
CU20200053A7 (es) 2021-03-11
MA49956B1 (fr) 2022-11-30
CU24671B1 (es) 2023-07-12
JP7218364B2 (ja) 2023-02-06
US20200140430A1 (en) 2020-05-07
TW201930304A (zh) 2019-08-01

Similar Documents

Publication Publication Date Title
PH12020500528A1 (en) Pyrimidine compound as jak kinase inhibitor
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
PH12017502050B1 (en) Naphthyridine compounds as jak kinase inhibitors
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
MX2018013191A (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12020500201A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
PH12017502407A1 (en) Fused pyrimidine compound or salt thereof
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
AU2018337138A1 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
CR20200267A (es) Polimorfos
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
MY192305A (en) Bipyrazole derivatives as jak inhibitors